Costimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus

Human Gene Therapy

Volumn 10, Issue 13, 1999, Pages 2221-2236

  Pollok, Karen E ^a   Van Der Loo, Johannes C M ^a,b   Cooper, Ryan J ^a   Kennedy, Lorrie ^a   Williams, David A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; COMPLEMENTARY DNA; CYCLOHEXIMIDE; INTERLEUKIN 2; PHOSPHOGLYCERATE KINASE; PROTEIN KINASE INHIBITOR; VIRUS DNA;

ARTICLE; CELL CYCLE; COMPLEX FORMATION; CYTOMEGALOVIRUS; GENE EXPRESSION; GENE NUMBER; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MOLONEY LEUKEMIA ONCOVIRUS; PROTEIN PROTEIN INTERACTION; PROVIRUS; RETROVIRUS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TRANSCRIPTION REGULATION; TRANSGENE; VIRUS TRANSCRIPTION;

ANTIBODIES; ANTIGENS, CD28; CELLS, CULTURED; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INTERLEUKIN-2; MOLONEY MURINE LEUKEMIA VIRUS; RECEPTOR-CD3 COMPLEX, ANTIGEN, T-CELL; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 0033199826     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950017202     Document Type: Article

References (70)

1. AGARWAL, M., AUSTIN, T.W., MOREL, F., CHEN, J., BOHNLEIN, E., and PLAVEC, I. (1998). Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J. Virol. 72, 3720-3728.
2. ALESSI, D.R., CUENDA, A., COHEN, P., DUDLEY, D.T., and SALTIEL, A.R. (1995). PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem. 270, 27489-27494.
3. BAUM, C., ITOH, K., MEYER, J., LAKER, C., ITO, Y., and OSTERTAG, W. (1997). The potent enhancer activity of the polycythemic strain of spleen focus-forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core motif, creating an exclusive target for PEBP/CBF. J. Virol. 71, 6323-6331.
4. -SCID: Initial trial results after 4 years. Science 270, 475-480.
5. + bone marrow cells. Blood 82, 1975-1980.
6. BONINI, C., FERRARI, G., VERZELETTI, S., SERVIDA, P., ZAPPONE, E., RUGGIERI, L., PONZONI, M., ROSSINI, S., MAVILIO, F., TRAVERSARI, C., and BORDIGNON, C. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719-1724.
7. - immunodeficient patients. Science 270, 470-475.
8. BUNNELL, B.A., MUUL, L.M., DONAHUE, R.E., BLAESE. R.M., and MORGAN, R.A. (1995). High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 92, 7739-7743.
9. + T lymphocytes in nonhuman primates using a gibbon ape leukemia virus-derived retroviral vector. Blood 89, 1987-1995.
10. CANTRELL, D. (1996). T cell antigen receptor signal transduction pathways. Annu. Rev. Immunol. 14, 259-274.
11. CEPKO, C. (1996). Preparation of a specific retrovirus producer cell line. In Current Protocols in Molecular Biology. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, and J.G. Seidman, eds. (John Wiley & Sons, New York) pp. 9.10.5-9.10.8.
12. CHALLITA, P.M., and KOHN, D.B. (1994). Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc. Natl. Acad. Sci. U.S.A. 91, 2567-2571.
13. CHALLITA, P.M., SKELETON, D., EL-KHOUEIRY, A., YU, X.J., WEINBERG, K.I., and KOHN, D.B. (1995). Multiple modifications in cis-elements of the LTR of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma (EC) cells. J. Virol. 69, 748-755.
14. CHIU, L., CHERWINSKI, H., RANSOM, J., and DUNNE, J.F. (1996). Flow cytometric ratio analysis of the Hoechst 33342 emission spectrum: Multiparametric characterization of apoptotic lymphocytes. J. Immunol. Methods 189, 157-171.
15. CHUCK, A.S., and PALSSON, B.O. (1996). Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titers. Hum. Gene Ther. 7, 743-750.
16. CRAWLEY, J.B., RAWLINSON, L., LALI, F.V., PAGE, T.H., SAKLATVALA, J., and FOXWELL, B.M. (1997). T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. J. Biol. Chem. 272, 15023-15027.
17. CULVER, K.W., MORGAN, R.A., et al. (1990). In vivo expression and survival of gene modified T lymphocytes in rhesus monkeys. Hum. Gene Ther. 1, 2301-2338.
18. DARDALHON, V., NORAZ, N., POLLOK, K., REBOUISSOU, C., BOYER, M., BAKKER, A.Q., SPITS, H., and TAYLOR, N. (1999). Green fluorescent protein as a selectable marker of fibronectin-facilitated retroviral gene transfer in primary human T lymphocytes. Hum. Gene Ther. 10, 5-14.
19. DESILVA, D.R., JONES, E.A., FAVATA, M.F., JAFFEE, B.D., MAGOLDA, R.L., TRZASKOS, J.M., and SCHERLE, P.A. (1998). Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent nergy. J. Immunol. 160, 4175-4181.
20. DONAHUE, R.E., BUNNELL, B.A., ZINK, M.C., METZGER, M.E., WESTRO, R.P., KIRBY, M.R., UNANGST, T., CLEMENTS, J.E., and MORGAN, R.A. (1998). Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes. Nature Med. 4, 181-186.
21. FEHSE, B., SCHADE, U.M., LI, Z., UHDE, A., KOCH, S., GOLLER, B., RUGER, R., FEHSE, N., STOCKSCHLADER, M., and ZANDER, A.R. (1998). Highly efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectin. Br. J. Hematol. 102, 566-574.
22. FLANAGAN, J.R., KRIEG, A.M., MAX, E.E., and KHAN, A.S. (1989). Negative control region at the 5′ end of murine leukemia virus long terminal repeats. Mol. Cell. Biol. 9, 739-746.
23. FLANAGAN, J.R., BECKER, K.G., ENNIST, D.L., GLEASON, S.L., DRIGGERS, P.H., LEVI, B.Z., APPELLA, E., and OZATO, K. (1992). Cloning of a negative transcription factor that binds to the upstream conserved region of Moloney murine leukemia virus. Mol. Cell. Biol. 12, 38-44.
24. GHAZAL, P., LUBON, H., REYNOLDS-KOHLER, C., HENNING-HAUSEN, L., and NELSON, J.A. (1990). Interactions between cellular regulatory proteins and a unique sequence region in the human cytomegalovirus major immediate-early promoter. Virology 174, 18-25.
25. GHAZIZADEH, S., CARROLL, J.M., and TAICHMAN, L.B. (1997). Repression of retrovirus-mediated transgene expression by interferons: Implications for gene therapy. J. Virol. 71, 9163-9169.
26. GREENBERG, M.E., and BENDER, T.P. (1994). Identification of newly transcribed RNA. In Current Protocols in Molecular Biology. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, and J.G. Seidman, eds. (John Wiley & Sons, New York) pp. 4.10.1-4.10.11.
27. GUNNING, P., PONTE, P., OKAYAMA, H., ENGEL, J., BLAU, H., and KEDES, L. (1983). Isolation and characterization of full length cDNA clones for human α-, β-, and γ-actin mRNAs: Skeletal but not cytoplasmic actins have an amino-terminal cysteine that is subsequently removed. Mol. Cell. Biol. 3, 787-795.
28. HANENBERG, H., XIAO, X.L., DILLOO, D., HASHINO, K., KATO, I., and WILLIAMS, D.A. (1996). Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nature Med. 2, 876-882.
29. + hematopoietic cells. Hum. Gene Ther. 8, 2193-2206.
30. HARMS, J.S., and SPLITTER, G.A. (1995). Interferon-γ inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum. Gene Ther. 6, 1291-1297.
31. HEGE, K.M., and ROBERTS, M.R. (1996). T-cell gene therapy. Curr. Opin. Biotechnol. 7, 629-634.
32. HESLOP, H.E., NG, C.Y., LI, C., SMITH, C.A., LOFTIN, S.K., KRANCE, R.A., BRENNER, M.K., and ROONEY, C.M. (1996). Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med. 2, 551-555.
33. HOCK, R.A., MILLER, A.D., et al. (1989). Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines. Blood 74, 876-881.
34. KALEKO, M., GARCIA, J.V., OSBORNE, W.R.A., and MILLER, A.D. (1990). Expression of human adenosine deaminase in mice after transplantation of genetically-modified bone marrow. Blood 75, 1733-1741.
35. KALLI, K., HUNTOON, C., BELL, M., and McKEAN, D.J. (1998). Mechanism responsible for T-cell antigen receptor- and CD28-or interleukin 1 (IL-1 ) receptor-initiated regulation of IL-2 gene expression by NF-κB. Mol. Cell. Biol. 18, 3140-3148.
36. KAPTEIN, L.C., VAN BEUSECHEM, V.W., RIVIERE, I., MULLIGAN, R.C., and VALERIO, D. (1997). Long-term in vivo expression of the MFC-ADA retroviral vector in rhesus monkeys transplanted with transduced bone marrow cells. Hum. Gene Ther. 8, 1605-1610.
37. KIM, S.H., YU, S.S., PARK, J.S., ROBBINS, P.D., AN, C.S., and KIM, S. (1998). Construction of retroviral vectors with improved safety, gene expression, and versatility. J. Virol. 72, 994-1004.
38. KIMIZUKA, F., TAGUCHI, Y., OHDATE, Y., KAWASE, Y., SHIMOJO, HASHING, K., KATO, I.., SEKIGUCHI, K., and TITANI, K. (1991). Production and characterization of functional domains of human fibronectin expressed in Escherichia coli. J. Biochem. 110, 284-291.
39. KOHN, D.B. (1997). Gene therapy for haematopoietic and lymphoid disorders. Clin. Exp. Immunol. 107, 54-57.
40. KOTANI, H., NEWTON, P.B., 3rd, ZHANG, S., CHIANG, Y.L., OTTO, E., WEAVER, L., BLAESE, R.M., ANDERSON, W.F., and McGARRITY, G.J. (1994). Improved methods of retroviral vector transduction and production for gene therapy. Hum. Gene Ther. 5, 19-28.
41. LAU, L.F., and NATHANS, D. (1987). Expression of a set of growth-related immediate early genes in Balb.C 3T3 cells: Coordinate regulation with c-fos or c-myc. Proc. Natl. Acad. Sci. U.S.A. 84, 1182-1186.
42. LINDSTEN, T., JUNE, C.H., and THOMPSON, C.B. (1988). Multiple mechanisms regulate c-myc gene expression during normal T cell activation. EMBO J. 7, 2787-2794.
43. LINDSTEN, T., JUNE, C.H., LEDBETTER, J.A., STELLA, G., and THOMPSON, C.B. (1989). Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science. 244, 339-343.
44. LU, M., ZHANG, N., et al. (1996). Retrovirus-mediated gene expression in hematopoietic cells correlates inversely with growth factor stimulation. Hum. Gene Ther. 7, 2263-2271.
45. MALIK, P., KRALL, W.J., YU, X.J., ZHOU, C., and KOHN, D.B. (1995). Retroviral-mediated gene expression in human myelomonocytic cells: A comparison of hematopoietic cell promoters to viral promoters. Blood 86, 2993-3005.
46. + cells that mediate long-term engraftment of NOD/SCID by HIV vectors. Science 283, 682-686.
47. MORITZ, T., KELLER, D.C., and WILLIAMS, D.A. (1993). Human cord blood cells as targets for gene transfer: Potential use in genetic therapies of severe combined immunodeficiency disease. J. Exp. Med. 178, 529-536.
48. NALDINI, L., BLOMER, U., GALLAY, P., ORY, D., MULLIGAN, R., GAGE, F.H., VERMA, I.M., and TRONO, D. (1996). In vivo delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267.
49. PAGES, F., RAGUENEAU, M., ROTTAPEL, R., TRUNEH, A., NUNES, J., IMBERT, J., and OLLVE, D. (1994). Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling. Nature (London) 369, 327-329.
50. PALMER, T.D., ROSMAN, G.J., OSBORNE, W.R., and MILLER, A.D. (1991). Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. U.S.A. 88, 1330-1334.
51. PLAVEC, I., AGARWAL, M., HO, K.E., PINEDA, M., AUTEN, J., BAKER, J., MATSUZAKI, H., ESCAICH, S., BONYHADI, M., and BOHNLEIN, E. (1997). High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: Implications for gene therapy of AIDS. Gene Ther. 4, 128-139.
52. POLLOK, K.E., HANENBERG, H., NOBLITT, T.W., SCHROEDER, W.L., KATO, I., EMANUEL, D., and WILLIAMS, D.A. (1998). High-efficiency gene transfer into normal and adenosine deaminase-deficient T-lymphocytes is mediated by transduction on recombinant fibronectin fragments. J. Virol. 72, 4882-4892.
53. QIN, L., DING, Y., PAHUD, D.R., CHANG, E., IMPERIALE, M.J., and BROMBERG, J.S. (1997). Promoter attenuation in gene therapy: Interferon-γ and tumor necrosis factor-α inhibit transgene expression. Hum. Gene Ther. 8, 2019-2029.
54. QUINN, E.R., LUM, L.G., and TREVOR, K.T. (1998). T cell activation modulates retrovirus-mediated gene expression. Hum. Gene Ther. 9, 1457-1467.
55. RANGA, U., WOFFENDIN, C., YANG, Z., XU, L., VERMA, S., LITTMAN, D.R., and NABEL, G.J. (1997). Cell and viral regulatory elements enhance the expression and function of a human immunodeficiency virus inhibitory gene. J. Virol. 71, 7020-7029.
56. REIF, K., and CANTRELL, D.A. (1998). Networking Rho family GT-Pases in lymphocytes. Immunity 8, 395-401.
57. RIDDELL, S.R., ELLIOTT, M., LEWINSOHN, D.A., GILBERT, M.J., WILSON, L., MANLEY, S.A., LUPTON, S.D., OVERELL, R.W., REYNOLDS, T.C., COREY, L., and GREENBERG, P.D. (1996). T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nature Med. 2, 216-223.
58. RIVIERE, I., BROSE, K., and MULLIGAN, R.C. (1995). Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. U.S.A. 92, 6733-6737.
59. ROBBINS, P.B., YU, X.J., SKELTON, D.M., PEPPER, K.A., WASSERMAN, R.M., ZHU, L., and KOHN, D.B. (1997). Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells. J. Virol. 71, 9466-9474.
60. ROBBINS, P.B., SKELTON, D.C., YU, X.J., HALENE, S., LEONARD, E.H., and KOHN, D.B. (1998). Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 95, 10182-10187.
61. ROONEY, C.M., SMITH, C.A., NG, C.Y.C., LOFTIN, S., LI, C., KRANCE, R.A., BRENNER, M.K., and HESLOP, E.H. (1995). Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus related lymphoproliferation. Lancet 345, 9-13.
62. ROSENBERG, S.A. (1997). Human gene marker/therapy clinical protocols. Hum. Gene Ther. 8, 2301-2338.
63. SCHAFER, P.H., WANG, L., WADSWORTH, S.A., DAVIS, J.E., and SIEKIERKA, J.J. (1999). T cell activation signals up-regulated p38 mitogen-activated protein kinase activity and induce TNF-α production in a manner distinct from LPS-activation of monocytes. J. Immunol. 162, 659-668.
64. SIEFKEN, R., KLEIN-HESSLING, S., SERFLING, E., KURRLE, R., and SCHWINZER, R. (1998). A CD28-associated signaling pathway leading to cytokine gene transcription and T cell proliferation without TCR engagement. J. Immunol. 161, 1645-1651.
65. SPECK, N.A., and BALTIMORE, D. (1987). Six distinct nuclear factors interact with the 75-base-pair repeat of the Moloney murine leukemia virus enhancer. Mol. Cell. Biol. 7, 1101-1110.
66. SPECK, N.A., RENJIFO, B., and HOPKINS, N. (1990). Point mutations in the Moloney murine leukemia virus enhancer identify a lymphoid-specific viral core motif and 1,3-phorbol myristate acetate-inducible element. J. Virol. 64, 543-550.
67. VAN BEUSECHEM, W., KUKLER, A., HEIDT, P.J., and VALERIO, D. (1992). Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells. Proc. Natl. Acad. Sci. U.S.A. 89, 7640-7644.
68. VLAHOS, C.J., MATTER, W.F., HUI, K.Y., and BROWN, R.F. (1994). A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 7, 5241-5248.
69. WANG, L., ROBBINS, P.B., CARBONARO, D.A., and KOHN, D.B. (1998). High-resolution analysis of cytosine methylation in the 5′ long terminal repeat of retroviral vectors. Hum. Gene Ther. 9, 2321-2330.
70. YANG, A.-G., ZHANG, X., TORTI, F., and CHEN, S.-Y. (1998). Anti-HIV type I activity of wild-type and functional defective RANTES intrakine in primary human lymphocytes. Hum. Gene Ther. 9, 2005-2018.